Eckert & Ziegler Radiopharma

Berlin, Germany
Radiopharmaceuticals (alpha, beta, gamma) Radioligand Therapy (RLT) PET diagnostics (F-18, Ga-68) Therapeutic isotopes (Lu-177, Ac-225) Radioactive medical devices Isotope production & supply Radiolabeling/conjugation
Program data pending ClinicalTrials.gov matching
60.0
Signal Score
○ FDA Inspections ○ Clinical Trials ○ SEC Filings ✓ Press (10) ○ EMA GMP ○ MHRA GMP

Quick Facts: Eckert & Ziegler Radiopharma

Signal Score
60.0/100
Quality Compliance
Assessment pending
Headquarters
Berlin, Germany
Modalities
Radiopharmaceuticals (alpha, beta, gamma), Radioligand Therapy (RLT), PET diagnostics (F-18, Ga-68), Therapeutic isotopes (Lu-177, Ac-225), Radioactive medical devices, Isotope production & supply, Radiolabeling/conjugation
Active Programs
No ClinicalTrials.gov matches confirmed
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About Eckert & Ziegler Radiopharma

Auto-created by AI matchmaker. Data verification pending.

Signal Score & Pillar Breakdown

Quality Compliance
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs no verified data
Sponsorsno verified data
ModalitiesRadiopharmaceuticals (alpha, beta, gamma), Radioligand Therapy (RLT), PET diagnostics (F-18, Ga-68), Therapeutic isotopes (Lu-177, Ac-225), Radioactive medical devices, Isotope production & supply, Radiolabeling/conjugation
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability 60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity 60.0
Broad modality coverage (7 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Recent Press10 articles
Broad modality coverage (7 modalities)

Recent News 10 articles

news Tue, 19 Ma
FA considers charging Southampton manager Tonda Eckert with misconduct over spying scandal - the-independent.com
news Tue, 02 Ju
Spygate: Southampton owner Dragan Solak will not sack head coach Tonda Eckert - BBC
news Tue, 02 Ju
'You legend - manager loved it' - Sky Sports
news Thu, 21 Ma
Spygate: Who is Tonda Eckert and can he keep his job? - BBC
news Thu, 21 Ma
Spygate: Southampton head coach Tonda Eckert authorised spying, panel says - BBC
news Thu, 21 Ma
Spygate news: Damning Tonda Eckert verdict as FA investigate and Southampton sack decision looms - The Mirror
news Sun, 28 Ju
Eckert & Ziegler strategy in nuclear medicine, shares on Xetra in a cautious sector - AD HOC NEWS
news Mon, 29 Ju
Woodhaven graduate turns life-changing injury into novel - thenewsherald.com
news Mon, 01 Ju
‘Manager loved it’: Tonda Eckert found to have initiated Southampton’s spying - The Guardian
news Fri, 26 Ju
Brian J. Eckert Obituary (1983 - 2026) - Philadelphia, Pennsylvania - Murphy Ruffenach Brian W. Donnelly Funeral Home

Frequently Asked Questions About Eckert & Ziegler Radiopharma

What is Eckert & Ziegler Radiopharma's CDMO Signal Score?
Eckert & Ziegler Radiopharma has a Signal Score of 60/100, based on quality, operations, financial stability, and capacity data.
Evaluating Eckert & Ziegler Radiopharma for a manufacturing program?
Use the free AI matchmaker to compare Eckert & Ziegler Radiopharma against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.